- How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort
-
Fotopoulou C
- KMID: 2465193
- J Gynecol Oncol.
- 2020 Apr;31(1):e26.
- doi: 10.3802/jgo.2020.31.e26
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
-
Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY
- KMID: 2471913
- Yonsei Med J.
- 2020 Apr;61(4):284-290.
- doi: 10.3349/ymj.2020.61.4.284
PURPOSE: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian... -
- CITED
-
- Close
- SHARE
-
- Close
- Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
-
Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno J, Cardenas-Goicoechea J
- KMID: 2471759
- Obstet Gynecol Sci.
- 2020 Mar;63(2):205-208.
- doi: 10.5468/ogs.2020.63.2.205
A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1... -
- CITED
-
- Close
- SHARE
-
- Close
- Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study
-
Carbajal-Mamani SL, Schweer D, Markham MJ, Esnakula A, Grajo JR, Castagno J, Cardenas-Goicoechea J
- KMID: 2471752
- Obstet Gynecol Sci.
- 2020 Mar;63(2):150-157.
- doi: 10.5468/ogs.2020.63.2.150
OBJECTIVE: The primary objective was to assess the feasibility of robotic-assisted interval cytoreductive surgery for achieving complete cytoreduction for patients with advanced-stage ovarian cancer. The secondary objective was to examine... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
-
Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT
- KMID: 2470873
- J Gynecol Oncol.
- 2020 Mar;31(2):e23.
- doi: 10.3802/jgo.2020.31.e23
OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen. METHODS: A retrospective study of patients diagnosed... -
- CITED
-
- Close
- SHARE
-
- Close
- Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
-
Tozzi R, Ferrari F, Nieuwstad , Campanile , Soleymani Majd H
- KMID: 2470867
- J Gynecol Oncol.
- 2020 Mar;31(2):e14.
- doi: 10.3802/jgo.2020.31.e14
OBJECTIVE: To introduce a systematic classification of diaphragmatic surgery in patients with ovarian cancer based on disease spread and surgical complexity. METHODS: For all consecutive patients who underwent diaphragmatic surgery during... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis
-
Lv X, Cui S, Zhang X, Ren C
- KMID: 2470865
- J Gynecol Oncol.
- 2020 Mar;31(2):e12.
- doi: 10.3802/jgo.2020.31.e12
OBJECTIVE: Neoadjuvant chemotherapy (NACT) for the treatment of epithelial ovarian cancer (EOC) has remained controversial. This meta-analysis was performed to systematically assess the efficacy and safety of NACT versus primary... -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
-
Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP
- KMID: 2465191
- J Gynecol Oncol.
- 2020 Jan;31(1):e17.
- doi: 10.3802/jgo.2020.31.e17
OBJECTIVE: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) confers similar outcomes as primary debulking surgery and chemotherapy. Little is known about patients who receive NACT but do not... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer
-
Günakan E, Tohma YA, Tunç M, Akıllı H, Şahin H, Ayhan A
- KMID: 2467933
- Obstet Gynecol Sci.
- 2020 Jan;63(1):64-71.
- doi: 10.5468/ogs.2020.63.1.64
OBJECTIVE: Epithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background.... -
- CITED
-
- Close
- SHARE
-
- Close
- Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients
-
Lee SH, Lee H, Lim MC, Kim S
- KMID: 2465979
- Korean J Women Health Nurs.
- 2019 Dec;25(4):365-378.
- doi: 10.4069/kjwhn.2019.25.4.365
PURPOSE: The awareness of hereditary breast and ovarian cancer (HBOC) and BRCA testing is increasing in Korea. Compared to the sizable research on HBOC knowledge among breast cancer women, studies... -
- CITED
-
- Close
- SHARE
-
- Close
- MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B
-
Niu Q, Liu Z, Gao J, Wang Q
- KMID: 2463793
- Yonsei Med J.
- 2019 Dec;60(12):1146-1156.
- doi: 10.3349/ymj.2019.60.12.1146
PURPOSE: Chemoresistance is a concern in ovarian cancer patients, in whom survival remains. MicroRNA, a novel class of small RNAs, have frequently been found to be dysregulated in human malignancies... -
- CITED
-
- Close
- SHARE
-
- Close
- Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
-
Zang R, Zhu J
- KMID: 2458912
- J Gynecol Oncol.
- 2019 Nov;30(6):e116.
- doi: 10.3802/jgo.2019.30.e116
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
-
Machida H, Matsuo K, Enomoto T, Mikami M
- KMID: 2458909
- J Gynecol Oncol.
- 2019 Nov;30(6):e113.
- doi: 10.3802/jgo.2019.30.e113
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
-
Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG, on behalf of KGOG investigators
- KMID: 2458908
- J Gynecol Oncol.
- 2019 Nov;30(6):e112.
- doi: 10.3802/jgo.2019.30.e112
BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed... -
- CITED
-
- Close
- SHARE
-
- Close
- Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
-
Batista TP, Kusamura S
- KMID: 2458907
- J Gynecol Oncol.
- 2019 Nov;30(6):e111.
- doi: 10.3802/jgo.2019.30.e111
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
-
Cheng H, Huo L, Wang D, Xiang Y
- KMID: 2458902
- J Gynecol Oncol.
- 2019 Nov;30(6):e99.
- doi: 10.3802/jgo.2019.30.e99
OBJECTIVE: To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS: The medical records of 23 consecutive patients who were diagnosed with OC... -
- CITED
-
- Close
- SHARE
-
- Close
- Relationship between the precursors of high grade serous ovarian cancer and patient characteristics: decreased incidence of the p53 signature in pregnant women
-
Ida T, Fujiwara H, Kiriu T, Taniguchi , Kohyama A
- KMID: 2458901
- J Gynecol Oncol.
- 2019 Nov;30(6):e96.
- doi: 10.3802/jgo.2019.30.e96
OBJECTIVE: To investigate the relationship between the precursors of high grade serous ovarian cancer (HGSOC) and the characteristics of patients with a low HGSOC risk in terms of the effects... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer
-
Chambers L, Son J, Radeva M, DeBernardo R
- KMID: 2458898
- J Gynecol Oncol.
- 2019 Nov;30(6):e93.
- doi: 10.3802/jgo.2019.30.e93
OBJECTIVE: To identify factors associated with non-completion of intraperitoneal with intravenous chemotherapy [IP/IV] in women with epithelial ovarian cancer (EOC). METHODS: This was an Institutional Review Board approved, retrospective cohort study... -
- CITED
-
- Close
- SHARE
-
- Close
- Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer
-
Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT
- KMID: 2459144
- Yonsei Med J.
- 2019 Oct;60(10):914-923.
- doi: 10.3349/ymj.2019.60.10.914
PURPOSE: Few efforts have been made to integrate a next generation sequencing (NGS) panel into standard clinical treatment of ovarian cancer. The aim of this study was to investigate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Response to comment on: prior uterine myoma and risk of ovarian cancer: a population-based case-control study
-
Huang CC, Lin CH
- KMID: 2457168
- J Gynecol Oncol.
- 2019 Sep;30(5):e109.
- doi: 10.3802/jgo.2019.30.e109
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
